Enhertu for Breast Cancer: Uses, Dosage, and Cost

Enhertu contains the active drug fam-trastuzumab deruxtecan-nxki. It is an FDA-approved HER2-directed antibody and topoisomerase inhibitor conjugate. Commercially supplied as 100 mg vials in the market, it may also be known as trastuzumab deruxtecan, or T-DXd. Enhertu 100 mg is developed by Daiichi Sankyo and is promoted by AstraZeneca (AZ) globally.

Enhertu Uses for Breast Cancer: Enhertu is approved by the FDA for the treatment of adults with breast cancer that is either:

HER2-positive: These are tumors that grow quickly because of higher levels of a protein named  HER2 or human epidermal growth factor receptor 2. As per Breast Cancer Foundation, 15-20 % of breast cancers are HER2-positive, and these cancers tend to progress faster.

HER2-low: This newer term basically describes tumors that have HER2 but are not sufficient to be considered positive. Earlier these tumors would have been classified as HER2-negative. Now up to 60 percent of breast cancers are HER2-low.

More specifically, the medicine Enhertu injection is considered when these tumors are either metastatic (meaning it has spread from their initial location to distant body parts), or unresectable (meaning they can't be removed surgically).

Prior to starting Enhertu, patients must also have already been treated with other therapies (anti-HER2 therapy for HER2 +Ve cancer, or chemotherapy for HER2-low) for metastatic cancer, or had a recurrence within six months following completing these previous therapies.

Other Uses of Enhertu (fam-trastuzumab deruxtecan-nxki):

 Enhertu 100 mg injection may also be given to individuals who have:

• NSCLC, that has a specific mutation named HER2, which is unable to be removed with surgery or has metastasized, and has already been treated.
• HER2 +Ve gastric or gastroesophageal junction adenocarcinoma stomach cancer that has spread and has already been treated.

Enhertu Dosage & Administration:

Enhertu is typically administered intravenously (IV) through a method known as infusion therapy. It is an ADC, a type of targeted medicine, meaning it travels to the tumor and releases chemo to the cells that produce excess HER2, directly destroying the cells that cause harm to the body.  A dose of 5.4 mg/kg of body weight is typically given once every 21 days. Treatment duration may vary, with 7 months being the midrange treatment.

Enhertu Injection Cost & Availability:

Enhertu cost in India is mostly influenced due to the lack of easy access. Patients can consider several options that are cost-effective. Enhertu is a lifesaving medicinal product that is not (yet) available in India. But can be legally accessed from an experienced service provider Indian Pharma Network (IPN). We are specialized in delivering specialty medicinal products like sourcing Enhertu 100 mg injection in India.

Kindly WhatsApp/Call: +91 9310090915 or dial our TOLL-FREE Number: 1800-889-1064 to buy Enhertu Online in India and other countries where the medicine is not (yet) approved.

Atriance Suppliers in India

For the proper handling and disposal of cytotoxic anti-tumour pharmaceuticals, the following procedures should be followed: 

Staff members must receive training on handling and transporting the medication.

You can now buy Atriance injection online in India through The Indian Pharma Network at an affordable price by going to our website at https://www.indianpharmanetwork.in/. We are a team of highly skilled specialists with more than 20 years of expertise in distributing speciality pharmaceuticals.

Atriance: Distributors in India

Despite the low Atriance injection price, this medicine is under closer observation. Healthcare professionals should report any potential harmful responses. There were insufficient numbers of patients 65 and older in clinical investigations using nelarabine to ascertain whether their responses differed from those of younger patients. Nelarabine was administered to a child patient in clinical tests at a dose of 75 mg/kg daily for 5 days, to 5 adult patients at a dose of 60 mg/kg (roughly 2,400 mg/m2) daily for 5 days, and to 2 additional adults on days 1, 3, and 5. For more information on Atriance, contact us by email at info@indianpharmanetwork.in.

Atriance: An FDA-approved medication

The FDA approved the medicine Nelarabine in 2005. According to an exploratory analysis, getting older—particularly older than 65—seemed linked to a higher incidence of neurological adverse events. Although it is packaged as Atriance 250mg 50 ml, overdose can occasionally occur. However, there haven't been any overdose reports. Nelarabine overdose is likely to result in fatal myelosuppression, severe neurotoxicity, and other side effects. Two patients who received 2200 mg/m2 on days 1, 3, and 5 every 21 days experienced significant grade 3 ascending sensory neuropathy. 

FDA approves Tibsovo (ivosidenib)

 Adult patients with susceptible IDH1 mutations discovered by an FDA-authorized test are treated with Tibsovo, an FDA-approved IDH1 inhibitor approved in 2018. One can take Tibsovo with or without meals. A high-fat meal should not be consumed with tibsovo since the concentration will increase. It is not recommended to split or divide Tibsovo tablets. Take Tibsovo pills orally at the same time each day. Wait until the following dosage is planned if you vomit and miss a Tibsovo dose. 

Tibsovo has the following drug interactions that patients should be aware of before using. If you require any further information, consult your doctor. Please get in touch with The Indian Pharma or send an email to info@indianpharmanetwork.in for further details about the Tibsovo cost. 

Tibsovo: Applications 

It is possible to get tibsovo tablets. Till the disease becomes worse or there is serious toxicity, Tibsovo should be used once a day. 

•  A kind of blood cancer called acute myeloid leukemia (AML). 

Recurrent or refractory AML should not be treated in patients over 75 with comorbidities prohibiting extensive induction chemotherapy. 

• Patients who had previously had therapy for either locally advanced or metastatic cholangiocarcinoma were found to have the illness. 

This is accessible with a valid prescription and from a reliable vendor like Indian Pharma Networks. Any generic and creative provider with the necessary authorization, a legitimate and acknowledged prescription, and adherence to the requirements may offer the drug. As one of the most dependable and trustworthy generic pharmaceutical suppliers, Indian Pharma Networks offers you to buy Tibsovo online at incredibly low costs. 

Tibsovo: Restricted Use 

Along with its advantages, tibsovo 250 mg has a few warnings and precautions, which are as follows: 

Checking for QTc interval prolongation should be done using minerals and electrocardiograms. Reducing or pausing the dosage, starting the dose, or stopping Tibsovo altogether should be done if QTc interval prolongation happens. 

Look for new motor and sensory abnormalities in individuals who may have Guillain-Barre syndrome (GBS) and the accompanying signs and symptoms. 

Tibsovo: Prohibited with other Drugs 

• Reduce your Tibsovo dose if you take a strong or moderate CYP3A4 inhibitor. Look for indications of a prolonged QTc interval in the individuals. 
• It is best to avoid using Tibsovo concurrently if you are a CYP3A4 inducer.
• Avoid using Tibsovo concurrently when using sensitive CYP3A4 substrates. 
• No medicine that lengthens QTc should be administered with tibsovo. If coadministration 
• is inevitable, patients should be closely watched for a heightened risk of QTc interval prolongation. 
• Your doctor may recommend a corticosteroid or hydroxyurea medication while watching you in the hospital if you exhibit symptoms of differentiation syndrome. 

This extremely powerful medication is freely available and may be purchased from any reputable vendor. Due to its low cost, Tibsovo is very simple to include in treatment programs in India. For more information on how much Tibsovo costs in India, please contact us at https://www.indianpharmanetwork.in/contact-us/. 

Tibsovo: Undesirable Effect 

Tibsovo is the brand name for ivosidenib-containing film-coated tablets. Among the inactive components are colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.

• Fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, and irregular ECG readings were the most frequent side effects in AML patients (20%). Rash, cough, reduced appetite, myalgia, constipation, and pyrexia are some of the symptoms of QT prolongation. 
• Hemoglobin decrease, calcium drop, sodium drop, magnesium drop, uric acid drop, potassium drop, alkaline phosphatase drop, aspartate aminotransferase drop, phosphate drop, and creatinine drop were the most prevalent laboratory abnormalities in AML patients (20%). 

This effective medication is available in India, and the price of Tibsovo is economical. 

Tibsovo: Availability in India 

Ivosidenib, a little medication, prevents the mutant isocitrate dehydrogenase 1 (IDH1) enzyme from functioning. The most prevalent mutations in AML patients are R132H and R132C.

Ivosidenib considerably decreased the dosage necessary to inhibit a variety of IDH1 R132 mutants in vitro compared to wild-type IDH1. By blocking the mutant IDH1 enzyme, ivosidenib reduced 2HG levels and improved myeloid development in mice xenograft models of AML with an IDH1 mutation both in vitro and in vivo. Ivosidenib therapy reduced ex-vivo 2-HG levels, blast numbers, and the proportion of mature myeloid cells in blood samples from persons with AML and mutant IDH1. 

Due to the inexpensive cost, wide availability, and simplicity of adding Tibsovo price in India. Since we are the most reputable suppliers in the country, please contact Indian Pharma Network at https://www.indianpharmanetwork.in/contact-us/ for more information. 

Tibsovo: Indian Pharma Network 

The drug Tibsovo is approved by Indian Pharma Network for treating patients with acute myeloid leukemia and cholangiocarcinoma.

• In patients with cholangiocarcinoma, the most frequent adverse effects were tiredness, nausea, stomach pain, diarrhea, coughing, reduced appetite, ascites, vomiting, anemia, and rash. 
• In 10% of cholangiocarcinoma patients, low hemoglobin, elevated aspartate aminotransferase, and high bilirubin were the most prevalent laboratory abnormalities. 

Indian Pharma Network is a fast-growing pharmaceutical consultancy and service company that offers reliable network access to life-saving medicines.

kineret fda approved indications

Patients with moderately to highly active rheumatoid arthritis who have received at least one disease-modifying antirheumatic medication (DMARD) but failed to manage signs and symptoms or delay the course of structural damage are prescribed Kineret injection. These patients must be 18 years of age or older. 

It is also used to treat Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Only with a prescription can one receive Kineret, and only a licensed physician should initiate and oversee treatment. 

Kineret: Process to Administer

There is a Kineret 100 mg/0.67 mL subcutaneous injectable solution available. Doses between 20 mg and 100 mg are possible with a graduated syringe. Kineret is injected subcutaneously, or beneath the skin, to deliver the medication. Kineret 100 mg once a day is the recommended dosage for treating rheumatoid arthritis, and it should be taken at around the same time each day. The dose for familial Mediterranean fever, Still's illness, and CAPS is based on the patient's weight and the severity of the ailment. Patients with CAPS must be at least 8 months old and 10 kg in weight to undergo therapy. Take 100 mg of COVID-19 once a day for 10 days.      

FDA-Approved Medication 

Kineret was given the go-ahead to treat RA and Cryopyrin-Associated Periodic Syndromes (CAPS) on November 14, 2001. Human interleukin-1 receptor antagonist (IL-1Ra) is marketed as Kineret (anakinra) and is available in the recombinant, non-glycosylated form. A single methionine residue has been added to the amino terminus of Kineret, which makes it different from native human IL-1Ra. Kineret has a molecular weight of 17.3 kilodaltons and 153 amino acids. It is created utilizing a bacterial expression system from E. coli and recombinant DNA technologies.

Kineret: Price in India

Glass single-use syringes with 27 gauge needles are used to deliver Kineret. Each prefilled glass syringe has a 0.67 mL volume and weighs 100 milligrammes of anakinra. Anakinra is included in 100 milligrams of the whole syringe. A 4 × 7 syringe dispensing pack with 28 syringes is available to administer Kineret.

Kineret is also offered in a single 7-syringe dispensing pack. Storage. Kineret should be kept between 2 and 8 degrees Celsius or 36 and 46 degrees Fahrenheit. It must be protected from light, not frozen, or disturbed.Kineret injection is offered reasonably and cost-effectively; therefore, we provide you with the lowest Kineret cost.

Kineret: Available as Injectables

The main component of Kineret is the immunosuppressive medication anakinra. Immunosuppressive drugs work by reducing immune system function. An artificial replica of a human protein called "human interleukin 1 receptor antagonist," anakinra blocks the body's interleukin 1 receptors. High levels of this interleukin production are seen in rheumatoid arthritis patients, which causes joint inflammation and, ultimately, joint damage. Additionally, it fuels the inflammation connected to CAPS, familial Mediterranean fever, and Still's illness. There is no binding site left because anakinra prevents the action of interleukin 1 by attaching to the receptors where interleukin 1 would ordinarily attach. The indications and symptoms of many ailments are eventually relieved.

Indian Pharma Network provides it, which you may get at a fair price. Contact us for more information on the kineret injection and price.

Undesirable effects

• Rheumatoid Arthritis (RA) The most prevalent side effects (incidence 5%) are injection site reactions, rheumatoid arthritis aggravation, upper respiratory tract infections, headaches, nausea, diarrhea, sinusitis, arthralgia, and stomach pain.
• NOMID

The most commonly reported adverse effects during the first six months of therapy were injection site reactions, headaches, vomiting, arthralgia, pyrexia, and nasopharyngitis.

Prohibited Usage

There have been no studies on medication interactions involving humans. The clearance or toxicologic profiles of either medication did not significantly change after methotrexate and Kineret administration to rats in toxicologic and toxicokinetic studies. 

TNF Blocking Agents: Studies have shown that patients taking concurrent Kineret and etanercept medication had more serious infections than patients getting etanercept alone. In 2% of individuals taking Kineret and etanercept concurrently, neutropenia (ANC 1 x 109/L) developed. Combining Kineret with TNF-blocking drugs is not recommended.

Kineret should only be used under the supervision of a licensed medical professional, and a prescription is required to obtain it. The  Kineret injection cost is moderate and fair; for more details, contact Indian Pharma Network. 

Dosage Strength

When a young person has NOMID, Kineret is advised for geriatric use. Due to the increased prevalence of infections in the senior population, care should be given while treating the elderly.

Renal dysfunction: Because this medicine is believed to be mostly removed through the kidneys, individuals with impaired renal function may be more vulnerable to negative drug responses. 

Kineret can only be obtained with a prescription; only a qualified medical professional should start and manage treatment. The cost of Kineret injection is reasonable and accessible; for additional details, see Kineret 100mg price.

Restricted Use 

Stop using the RA medication if a serious infection develops. Patients with NOMID should weigh the potential risks of quitting Kineret therapy against the possibility of a NOMID flare. Starting Kineret shouldn't be done by patients who have active infections. 

• Combining it with drugs that block tumor necrosis factor (TNF) is not recommended.
• There have been recorded cases of angioedema and anaphylactic reactions, among other hypersensitivity events. 
• Kineret treatment has not been demonstrated to affect the development of cancer or active or persistent infections.
• Live vaccines shouldn't be given combined with Kineret.
•  Before beginning Kineret therapy, neutrophil levels should be assessed every three months while on Kineret and then every six months for up to a year afterward. 
• The cost of Kineret 100 mg is fair and affordable; for more information, contact Indian Pharma Network by going to our website, https://www.indianpharmanetwork.in/.